ID

20007

Description

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT00336479

Link

https://clinicaltrials.gov/show/NCT00336479

Keywords

Versions (3)
  1. 2/2/17 2/2/17 -
  2. 2/2/17 2/2/17 -
  3. 2/3/17 2/3/17 -
Uploaded on

February 3, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Hepatitis C NCT00336479

English

Eligibility Chronic Hepatitis C NCT00336479

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
hepatitis c virus genotype 1 with detectable plasma hepatitis c virus rna
Description

Hepatitis C virus genotype 1 | Hepatitis C RNA Detectable

Data type

boolean

Alias
UMLS CUI [1]
C3532919
UMLS CUI [2,1]
C0855840
UMLS CUI [2,2]
C3830527
have been infected with hepatitis c virus for greater than (>) 6 months
Description

Hepatitis C virus infection Disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C3844790
UMLS CUI [1,2]
C0872146
seronegative for hepatitis b surface antigen and human immunodeficiency virus 1 and 2
Description

Hepatitis B Surface Antigens Seronegative | HIV-1 Seronegative | HIV-2 Seronegative

Data type

boolean

Alias
UMLS CUI [1,1]
C0019168
UMLS CUI [1,2]
C0521144
UMLS CUI [2,1]
C0019704
UMLS CUI [2,2]
C0521144
UMLS CUI [3,1]
C0019707
UMLS CUI [3,2]
C0521144
must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
Description

Childbearing Potential Contraceptive methods Quantity | Contraception, Barrier

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0004764
female subjects must have a negative pregnancy test at all visits before the first dose
Description

Gender Pregnancy test negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0427780
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
received any approved or investigational drug or drug regimen for the treatment of hepatitis c
Description

Pharmaceutical Preparations Approved Hepatitis C | Investigational New Drugs Hepatitis C

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205540
UMLS CUI [1,3]
C0019196
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C0019196
any medical contraindications to pegylated interferon alfa 2a or ribavirin therapy
Description

Medical contraindication peginterferon alfa-2a | Medical contraindication Ribavirin

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0391001
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0035525
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis or primary biliary cirrhosis
Description

Liver disease Significant Cause | Hepatitis C | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis

Data type

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C0015127
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0019163
UMLS CUI [4]
C1960179
UMLS CUI [5]
C0023891
UMLS CUI [6]
C0241910
UMLS CUI [7]
C0018995
UMLS CUI [8]
C0019202
UMLS CUI [9]
C3241937
UMLS CUI [10]
C0008312
diagnosed or suspected hepatocellular carcinoma
Description

Liver carcinoma | Liver carcinoma Suspected

Data type

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2,1]
C2239176
UMLS CUI [2,2]
C0332147
histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start
Description

Liver Cirrhosis Evidence Biopsy of liver | Compensated cirrhosis Biopsy of liver

Data type

boolean

Alias
UMLS CUI [1,1]
C0023890
UMLS CUI [1,2]
C0332120
UMLS CUI [1,3]
C0193388
UMLS CUI [2,1]
C1608426
UMLS CUI [2,2]
C0193388
alcohol abuse or excessive use in the last 12 months
Description

Alcohol abuse | Alcohol intake above recommended sensible limits

Data type

boolean

Alias
UMLS CUI [1]
C0085762
UMLS CUI [2]
C0560219
participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
Description

Study Subject Participation Status | Investigational New Drugs | Drug study Quantity Participation

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C0013175
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0679823
Back to the top of the page

Similar models

Eligibility Chronic Hepatitis C NCT00336479

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis C virus genotype 1 | Hepatitis C RNA Detectable
Item
hepatitis c virus genotype 1 with detectable plasma hepatitis c virus rna
boolean
C3532919 (UMLS CUI [1])
C0855840 (UMLS CUI [2,1])
C3830527 (UMLS CUI [2,2])
Hepatitis C virus infection Disease length
Item
have been infected with hepatitis c virus for greater than (>) 6 months
boolean
C3844790 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hepatitis B Surface Antigens Seronegative | HIV-1 Seronegative | HIV-2 Seronegative
Item
seronegative for hepatitis b surface antigen and human immunodeficiency virus 1 and 2
boolean
C0019168 (UMLS CUI [1,1])
C0521144 (UMLS CUI [1,2])
C0019704 (UMLS CUI [2,1])
C0521144 (UMLS CUI [2,2])
C0019707 (UMLS CUI [3,1])
C0521144 (UMLS CUI [3,2])
Childbearing Potential Contraceptive methods Quantity | Contraception, Barrier
Item
must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0004764 (UMLS CUI [2])
Gender Pregnancy test negative
Item
female subjects must have a negative pregnancy test at all visits before the first dose
boolean
C0079399 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Pharmaceutical Preparations Approved Hepatitis C | Investigational New Drugs Hepatitis C
Item
received any approved or investigational drug or drug regimen for the treatment of hepatitis c
boolean
C0013227 (UMLS CUI [1,1])
C0205540 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
Medical contraindication peginterferon alfa-2a | Medical contraindication Ribavirin
Item
any medical contraindications to pegylated interferon alfa 2a or ribavirin therapy
boolean
C1301624 (UMLS CUI [1,1])
C0391001 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0035525 (UMLS CUI [2,2])
Liver disease Significant Cause | Hepatitis C | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis
Item
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis or primary biliary cirrhosis
boolean
C0023895 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0015127 (UMLS CUI [1,3])
C0019196 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C1960179 (UMLS CUI [4])
C0023891 (UMLS CUI [5])
C0241910 (UMLS CUI [6])
C0018995 (UMLS CUI [7])
C0019202 (UMLS CUI [8])
C3241937 (UMLS CUI [9])
C0008312 (UMLS CUI [10])
Liver carcinoma | Liver carcinoma Suspected
Item
diagnosed or suspected hepatocellular carcinoma
boolean
C2239176 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0332147 (UMLS CUI [2,2])
Liver Cirrhosis Evidence Biopsy of liver | Compensated cirrhosis Biopsy of liver
Item
histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start
boolean
C0023890 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0193388 (UMLS CUI [1,3])
C1608426 (UMLS CUI [2,1])
C0193388 (UMLS CUI [2,2])
Alcohol abuse | Alcohol intake above recommended sensible limits
Item
alcohol abuse or excessive use in the last 12 months
boolean
C0085762 (UMLS CUI [1])
C0560219 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs | Drug study Quantity Participation
Item
participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013175 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0679823 (UMLS CUI [3,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial